<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-89519" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>EMS Pain Assessment And Management</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schwerin</surname>
            <given-names>Daniel L.</given-names>
          </name>
          <aff>Prisma Health-Upstate</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mohney</surname>
            <given-names>Stephen</given-names>
          </name>
          <aff>Geisinger</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Daniel Schwerin declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Stephen Mohney declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>21</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-89519.s1" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>In the United States of America, acute pain and the expectation of pain management is one of the primary reasons that prehospital providers receive calls. By definition from the International Association for the Study of Pain, "Pain is an unpleasant sensory and emotional experience associated with actual or potential tissue damage." As such, pain or the perception of pain can have both physiological and psychological impact on patients that interferes with their activities of daily living, causes a delay in healing and recovery, and ultimately impacting the quality of life of the patient.<xref ref-type="bibr" rid="article-89519.r1">[1]</xref><xref ref-type="bibr" rid="article-89519.r2">[2]</xref>&#x000a0;Based upon NEMSIS v2, 33.1% of the complaints to 911 are for pain-related syndromes, with chest pain accounting for 10.2% of all calls.<xref ref-type="bibr" rid="article-89519.r3">[3]</xref><xref ref-type="bibr" rid="article-89519.r4">[4]</xref> The most common provider impression based upon this 2016 data includes traumatic injuries at 21.8%, abdominal pain at 12.2%, and chest pain at 10%. This data means that almost half of all provider impressions are dealing with some form of a pain-related syndrome. A similar study looking at the national electronic prehospital patient records of 41,241 patients transported by emergency medical services (EMS) providers in Denmark showed a 28% moderate or severe pain level with an additional 32% of unknown pain status.<xref ref-type="bibr" rid="article-89519.r5">[5]</xref>&#x000a0;Galinski et al., in the prevalence and management of acute pain in the prehospital emergency medicine, indicated that 42% of the individuals having acute pain, with 64% of those patients having intense to severe pain.<xref ref-type="bibr" rid="article-89519.r6">[6]</xref>&#x000a0;The National Association of EMS Physicians (NAEMSP) believes that relieving the pain and suffering of patients is of necessity a priority for every EMS system. The 2018 EMS Scope of Practice Model looked at pain management for acute traumatic events as a high-priority issue requiring a systematic review of the literature.&#x000a0;</p>
        <p>Prehospital providers have to perform appropriate pain assessments and understand options for the treatment of acute pain. Pain assessment and treatment can be difficult based upon several different factors, including patient's age, race, location, EMS provider's ability or reluctance to administer pain medication, and the medical director's authority on the administration of pain medication. There is also a growing concern that the administration of opiate or opioid medication will cause addiction and abuse. One of the major hurdles for pain medication administration in the United States before 2014 was that prehospital providers would use standing orders to administer controlled substances for pain control. This administration of pain medication was based upon the 1970 Controlled Substances Act with an interpretation that EMS&#x000a0;providers&#x000a0;were allowed&#x000a0;to administer pain medication under the DEA registration of the medical director or hospital system. The DEA rejected standing orders for controlled substances for prehospital providers. Congress passed the Protecting Patient Access to Emergency Medications Act of 2017, which modified the Controlled Substances Act of 1970 to allow for EMS agencies to be registered with the DEA and use standing orders. The Act also gives specific instructions on the storage of controlled substances, provides for the restocking of EMS vehicles at hospitals, requires maintenance of controlled substance records, and holds the EMS agency liable for controlled substances.&#x000a0;</p>
      </sec>
      <sec id="article-89519.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>The 2003 position paper from NAEMSP believes that every EMS protocol should have (8) components: (1) mandatory assessment of both the presence and severity of pain, (2) use of reliable tools for the assessment of pain, (3) indications and contraindications for prehospital pain management, (4) non-pharmacologic interventions for pain management, (5) pharmacologic interventions for pain management, (6) mandatory patient monitoring and documentation before and after analgesic administration, (7) transferal of relevant patient care information to receiving medical personnel and (8) quality improvement and close medical oversight to ensure the appropriate&#x000a0;use of prehospital pain management.<xref ref-type="bibr" rid="article-89519.r7">[7]</xref> The Declaration of Montreal from the International Pain Summit indicates that the relief of pain is a global issue and that healthcare providers, including the prehospital providers, have a humanitarian responsibility to provide access and management of pain.<xref ref-type="bibr" rid="article-89519.r8">[8]</xref></p>
        <p>The problem at hand for most prehospital providers deals with the ability to perform an appropriate&#x000a0;pain assessment and then deciding which analgesia to use for the perceived pain. The measurement of pain and relief of pain is a complex entity with limited literature on education, research, agent availability, state and federal regulations on controlled substances, and the perception of pain based upon race, age, gender, and cultural beliefs. <xref ref-type="bibr" rid="article-89519.r9">[9]</xref> Porter et al. (1999) and Johnston et al. (1997) show that neonates undergoing painful procedures in the NICU rarely received analgesic agents (6.8% and 10% respectively), with the literature showing that early pain experiences can have long-term sequela to the patients.<xref ref-type="bibr" rid="article-89519.r10">[10]</xref><xref ref-type="bibr" rid="article-89519.r11">[11]</xref> Lord et al. concluded that there is no difference between genders receiving analgesia but did indicate that there is a difference between the types of&#x000a0;medication given.<xref ref-type="bibr" rid="article-89519.r12">[12]</xref> Perception of acute pain assessment and providing analgesia from paramedics shows that children and adolescents continue to receive fewer analgesic interventions compared to adults.<xref ref-type="bibr" rid="article-89519.r13">[13]</xref> Prehospital pain management has evolved over the years, and education on pain management has improved. In a six-year follow-up study, the knowledge, perceptions, and management of pain by paramedics from an urban/suburban fire department showed improvement for treating pain based upon the quality improvement program and educational interventions.<xref ref-type="bibr" rid="article-89519.r14">[14]</xref></p>
        <p>
<bold>Pain Assessment Tools</bold>
</p>
        <p>The use of validated pain assessment tools is an integral part of the assessment and treatment of patients with acute pain. Prehospital healthcare protocols or guidelines should include specific validated tools based upon the patient type to include age and ability to communicate.<xref ref-type="bibr" rid="article-89519.r15">[15]</xref>&#x000a0;There are several different pain scales based upon age that ranges from preterm to adulthood. Srouji et al. have listed over 20 different pain scales for preterm to 18 years of age.<xref ref-type="bibr" rid="article-89519.r11">[11]</xref> Additional scales include those for the non-verbal patients as well as those with dementia. The measurement of pain and pain intensity can be performed by several methods: behavioral, physiological measures, and self-reporting. The most widely used pain assessment scales utilize the self-reporting method, which has the most valid and optimal measurements, but these scales are limited in the pediatric population because of the cognitive and language development of children and lack of the younger child's ability to describe the pain.<xref ref-type="bibr" rid="article-89519.r11">[11]</xref> These scales also have limited utility for the non-verbal patient because of the inability to vocalize. Pain assessment for the younger patient, as well as the non-verbal patient, is then based upon the behavioral and physiological measurements. Body posture and movements, crying, and facial expressions are examples of behavioral measures. Physiological measures would include key vital signs of heart rate, blood pressure, respiration, and oxygen saturation, as well as palmer sweating and other neuroendocrine responses.<xref ref-type="bibr" rid="article-89519.r11">[11]</xref> Some popular tools include:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>NIPS Scale (Neonatal Infant Pain Scale)</bold>
<xref ref-type="bibr" rid="article-89519.r16">[16]</xref><bold/>
<list list-type="bullet"><list-item><p>Used in children less than one (1) year of age.&#x000a0;</p></list-item><list-item><p>Adapted from the CHEOPS scale and composed of six (6) indicators:
<list list-type="bullet"><list-item><p>Facial expression
<list list-type="bullet"><list-item><p>Score 0: Relaxed</p></list-item><list-item><p>Score 1: Grimace</p></list-item></list>
</p></list-item><list-item><p>Crying
<list list-type="bullet"><list-item><p>Score 0: No cry</p></list-item><list-item><p>Score 1: Whimper</p></list-item><list-item><p>Score 2: Vigorous crying</p></list-item></list>
</p></list-item><list-item><p>Breathing patterns
<list list-type="bullet"><list-item><p>Score 0: Relaxed</p></list-item><list-item><p>Score 1: Change in breathing</p></list-item></list>
</p></list-item><list-item><p>Arms
<list list-type="bullet"><list-item><p>Score 0: Restrained</p></list-item><list-item><p>Score 0: Relaxed</p></list-item><list-item><p>Score 1: Flexed</p></list-item><list-item><p>Score 1: Extended</p></list-item></list>
</p></list-item><list-item><p>Legs
<list list-type="bullet"><list-item><p>Score 0: Restrained</p></list-item><list-item><p>Score 0: Relaxed</p></list-item><list-item><p>Score 1: Flexed</p></list-item><list-item><p>Score 1: Extended</p></list-item></list>
</p></list-item><list-item><p>State of arousal
<list list-type="bullet"><list-item><p>Score 0: Sleeping</p></list-item><list-item><p>Score 0: Awake</p></list-item><list-item><p>Score 1: Fussy</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Pain Level
<list list-type="bullet"><list-item><p>0 - 2 = No pain to mild pain; no intervention</p></list-item><list-item><p>3 - 6 = Moderate pain; non-pharmacological intervention with a reassessment in 30 minutes</p></list-item><list-item><p>7 - 10 = Severe pain; non-pharmacological intervention and possibly a pharmacological intervention with a reassessment in 30 minutes</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>FLACC Scale (Face, Legs, Activity, Cry, Consolability)</bold>
<xref ref-type="bibr" rid="article-89519.r17">[17]</xref>&#x000a0;
<list list-type="bullet"><list-item><p>For children between the ages of two months and seven years. It can also be useful for individuals who are unable to communicate their pain, such as intubated adult patients in the intensive-care unit.<xref ref-type="bibr" rid="article-89519.r18">[18]</xref></p></list-item><list-item><p>The calculation of the total score is by adding the individual (5) criteria together for a resulting score from 0&#x000a0;to 10</p></list-item><list-item><p>Figure 1 for evaluation / download
<list list-type="bullet"><list-item><p>&#x000a0;Face
<list list-type="bullet"><list-item><p>Score 0: No facial expression or smile</p></list-item><list-item><p>Score 1: Occasionally grimaces or frowns; appears withdrawn, disinterested</p></list-item><list-item><p>Score 2: Frequently or constantly quivering chin, clenched jaw</p></list-item></list>
</p></list-item><list-item><p>&#x000a0;Legs
<list list-type="bullet"><list-item><p>Score 0: Normal position or relaxed</p></list-item><list-item><p>Score 1: Uneasy, restless, or tense</p></list-item><list-item><p>Score 2: Kicking or legs drawn up</p></list-item></list>
</p></list-item><list-item><p>&#x000a0;Activity
<list list-type="bullet"><list-item><p>Score 0: Lies quietly in a normal position and moves easily</p></list-item><list-item><p>Score 1: Squirms or shifts back and forth, tense</p></list-item><list-item><p>Score 2: Arched, rigid, or jerking</p></list-item></list>
</p></list-item><list-item><p>&#x000a0;Cry
<list list-type="bullet"><list-item><p>Score 0: No crying (awake or asleep)</p></list-item><list-item><p>Score 1: Moaning or whimpering; occasional complaining</p></list-item><list-item><p>Score 2: Steady crying, screaming or sobbing, frequent complaining</p></list-item></list>
</p></list-item><list-item><p>&#x000a0;Consolability
<list list-type="bullet"><list-item><p>Score 0: Content and relaxed</p></list-item><list-item><p>Score 1: Distractable, reassured by occasional touching, hugging, or being talked to</p></list-item><list-item><p>Score 2: Difficult to console</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Pain Level
<list list-type="bullet"><list-item><p>0 = No Pain</p></list-item><list-item><p>1 - 3 = Mild Pain</p></list-item><list-item><p>4 - 6 = Moderate Pain</p></list-item><list-item><p>7 - 10 = Severe Pain</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Wong-Baker FACES Pain Rating Scale <xref ref-type="bibr" rid="article-89519.r19">[19]</xref></bold>
<list list-type="bullet"><list-item><p>Created for children to help them communicate about their pain, it is now used for patients ages 3 to 18 years of age. This scale can be used with individuals that are impaired. The patient chooses from a series of faces that correlate to a numerical value.</p></list-item><list-item><p>Scale
<list list-type="bullet"><list-item><p>Smiling (0) - No hurt</p></list-item><list-item><p>Partial smile (2) - Hurts a little bit</p></list-item><list-item><p>Neutral (4) - Hurts a little more</p></list-item><list-item><p>Slight frown (6) - Hurts even more</p></list-item><list-item><p>Frowning (8) - Hours a whole lot</p></list-item><list-item><p>Crying (10) - Hurts worst</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Numeric Pain Rating Scale (NRS Pain) <xref ref-type="bibr" rid="article-89519.r20">[20]</xref></bold>
<list list-type="bullet"><list-item><p>One of the primary methods of patient pain assessment where the patient either circles or verbalizes the whole number (0 - 10 integers) corresponding to their pain intensity where (0) is no pain and (10) is extreme pain. There has been high test-retest reliability and validation for acute pain for this scale reported in both literate and illiterate patients.</p></list-item><list-item><p>Pain Level
<list list-type="bullet"><list-item><p>0 = No Pain</p></list-item><list-item><p>1 - 3 = Mild Pain; Nagging, annoying, interfering little with ADLs, person's ability to concentrate or think</p></list-item><list-item><p>4 - 6 = Moderate Pain; Interferes significantly with ADLs, person's ability to concentrate or think</p></list-item><list-item><p>7 - 10 = Severe Pain; Disabling, unable to perform ADLs, person's ability to concentrate or think</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Nonverbal Pain Scale (NVPS) for Nonverbal patients <xref ref-type="bibr" rid="article-89519.r1">[1]</xref></bold>
<list list-type="bullet"><list-item><p>Combination of behavioral and physiologic measurement for assessment of the non-verbal patient
<list list-type="bullet"><list-item><p>Face
<list list-type="bullet"><list-item><p>Score 0: No particular expression or smile</p></list-item><list-item><p>Score 1: Occasional grimace, tearing, frowning, wrinkled forehead</p></list-item><list-item><p>Score 2: Frequent grimace, tearing, frowning, wrinkled forehead</p></list-item></list>
</p></list-item><list-item><p>Activity (movement)
<list list-type="bullet"><list-item><p>Score 0: Lying quietly, normal position</p></list-item><list-item><p>Score 1: Seeking attention through movement or slow, cautious movement</p></list-item><list-item><p>Score 2: Restless, excessive activity, and/or withdrawal reflexes</p></list-item></list>
</p></list-item><list-item><p>Guarding
<list list-type="bullet"><list-item><p>Score 0: Lying quietly, no positioning of hands over areas of the body</p></list-item><list-item><p>Score 1: Splinting areas of the body, tense</p></list-item><list-item><p>Score 2: Rigid, stiff</p></list-item></list>
</p></list-item><list-item><p>Physiology (vital signs)
<list list-type="bullet"><list-item><p>Score 0: Baseline vital signs unchanged</p></list-item><list-item><p>Score 1: Changes in SBP &#x0003e; 20 mmHg or HR &#x0003e; 20 beats / minute</p></list-item><list-item><p>Score 2: Changes in SBP &#x0003e; 30 mmHg or HR &#x0003e; 25 beats / minute</p></list-item></list>
</p></list-item><list-item><p>Respiratory
<list list-type="bullet"><list-item><p>Score 0: Baseline RR / SpO2 synchronous with ventilator</p></list-item><list-item><p>Score 1: RR &#x0003e; 10 breaths / minute over baseline, 5% decrease SpO2 or mild ventilator asynchrony</p></list-item><list-item><p>Score 2: RR &#x0003e; 20 breaths / minute over baseline, 10% decrease SpO2 or severe ventilator asynchrony</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Pain Scores
<list list-type="bullet"><list-item><p>0 - 2 = No Pain to mild pain</p></list-item><list-item><p>3 - 6 = Moderate pain; consider analgesia. Sepsis, hypovolemia, and hypoxia need to be resolved prior to interventions</p></list-item><list-item><p>7 - 10 = Severe pain; consider analgesia. Sepsis, hypovolemia, and hypoxia need to be resolved prior to interventions</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p><bold>Pain Assessment in Advanced Dementia (PAINAD)</bold>
<list list-type="bullet"><list-item><p>Warden, Hurley, and Volicer developed this scale similar to the FLACC scale but used the 0 - 10 pain scale.&#x000a0;</p></list-item><list-item><p>The PAINED scale uses breathing, negative vocalization, facial expression, body language, and consolability as the criterion for pain.</p></list-item><list-item><p>Figure 1 for evaluation / download</p></list-item><list-item><p>Pain Scores
<list list-type="bullet"><list-item><p>0 = No pain</p></list-item><list-item><p>1 - 3 = Mild pain</p></list-item><list-item><p>4 - 6 = Moderate pain</p></list-item><list-item><p>7 - 10 = Severe pain</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>
<bold>Pain Management</bold>
</p>
        <p>Prehospital pain management can occur via non-pharmacologic and pharmacologic means. Pak et al. performed a review of the literature for non-pharmacological interventions for pain management, which includes distraction, stress management, hypnosis, acupuncture, acupressure, transcutaneous electrical nerve stimulation, and physical therapies (including massage, heat/cold, physiotherapy, osteopathy, and chiropractic).<xref ref-type="bibr" rid="article-89519.r21">[21]</xref> Additional treatment options for newborn and infant children include repositioning, singing or soft music, rocking the child, swaddling, use of a pacifier, gentle stroking, and allowing the newborn or infant to hold a comfort item or blanket. Oral sucrose administration, as well as breastfeeding or breast milk, can reduce the pain in newborns.<xref ref-type="bibr" rid="article-89519.r22">[22]</xref><xref ref-type="bibr" rid="article-89519.r16">[16]</xref></p>
        <p>Opiates, by and large, are the primary agents for pharmacologic pain management in the prehospital system, with morphine and fentanyl being the primary forms of opiates used.<xref ref-type="bibr" rid="article-89519.r23">[23]</xref>&#x000a0;Additional pharmacologic interventions would include NMDA receptor antagonists (ketamine), benzodiazepines (diazepam, lorazepam, and midazolam), nonsteroidal anti-inflammatories (ibuprofen, ketorolac), and other non-opiate pain medications (acetaminophen).</p>
        <list list-type="bullet">
          <list-item>
            <p>Non-opiate pain medication is considered one of the first-line treatment options for acute pain for non-healthcare individuals. The (2) primary classes include aniline analgesics and non-steroid anti-inflammatories. The primary mechanism of action for both NSAIDs and acetaminophen (which is a non-opiate analgesic) is by the reduction of prostaglandins in the brain by reducing cyclooxygenase (COX inhibitors). Additional non-opiate analgesic medications include nitroglycerin.
<list list-type="bullet"><list-item><p>Aniline analgesics are a class of medications first produced in 1886, with acetanilide being the first drug of this class with its major metabolite being paracetamol, but its use was stopped because of cyanosis due to methemoglobinemia. Phenacetin (synthesized by Bayer in 1887) and paracetamol (synthesized at Johns Hopkins University in 1887) are additional aniline derivatives. Phenacetin gained faster acceptance over paracetamol because the original thinking was that paracetamol to produced methemoglobinemia, but in the 1940s, research disproved this and determined that phenacetin metabolized to paracetamol. In the 1980s, phenacetin was banned secondary to hematological toxicity, analgesic nephropathy, and abuse due to psychotropic effects.
<list list-type="bullet"><list-item><p>Acetaminophen (para-acetylaminophenol or NPAP)
<list list-type="bullet"><list-item><p>First created in 1887 and has been one of the most commonly used pain and fever-reducing medications in the Americas and Europe. It has been listed by the World Health Organization (WHO) as an essential medication and is deemed safe in pregnancy. It has many medical uses, including fever reduction, mild to moderate pain management, and has been combined with opioids to improve analgesic effects. Adverse effects include liver damage (either in acute overdoses or with chronic use) via the toxic intermediate product NAPQI (N-acetyl-p-benzoquinone imine) and recent FDA warning about rare development of Stevens-Johnson syndrome and toxic epidermal necrolysis. Mechanism of action is with COX-2 inhibition and within the hypothalamus to produce antipyresis.</p></list-item><list-item><p>Para-acetylaminophenol breaks down into three separate metabolites via different processes that include: (1) glucuronidation, (2) sulfation, and (3) N-hydroxylation by cytochrome P-450.&#x000a0; NAPQI is the toxic metabolite produced during the N-hydroxylation process and reacts to sulfhydryl groups of glutathione to produce harmless metabolites.</p></list-item><list-item><p>Kinetics / dynamics
<list list-type="bullet"><list-item><p>Pregnancy category: C (crosses placenta)</p></list-item><list-item><p>Half-life: 1.25&#x000a0;to 3 hours</p></list-item><list-item><p>Onset: 10&#x000a0;to 60 minutes</p></list-item><list-item><p>Duration: 4&#x000a0;to 6 hours</p></list-item></list>
</p></list-item><list-item><p>Dosing
<list list-type="bullet"><list-item><p>Adult
<list list-type="bullet"><list-item><p>PO: 325&#x000a0;to 1000 mg every 4&#x000a0;to 6 hours NMT 4 grams/day</p></list-item></list>
</p></list-item><list-item><p>Pediatric
<list list-type="bullet"><list-item><p>PO: 10&#x000a0;to 15 mg/kg every 4&#x000a0;to 6 hours</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Precautions
<list list-type="bullet"><list-item><p>Potential toxic dose 150 mg/kg</p></list-item><list-item><p>Can cause allergic reaction/angioedema</p></list-item><list-item><p>Renally excreted in the sulfated and glucuronidated metabolite forms</p></list-item><list-item><p>10% metabolizes to NAPQI, which can, if it does not undergo glutathione conjugation, accumulate in the hepatocytes resulting in hepatic toxicity.</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Nonsteroidal anti-inflammatories (NSAIDs) break down into either COX-1 and COX-2 inhibitors, with both isozymes having a similar mechanism of action of inhibiting the breakdown of arachidonic acid with downstream reduction of prostaglandins, thromboxane, and prostacyclin.<xref ref-type="bibr" rid="article-89519.r24">[24]</xref> This class of medication, when not contraindicated, can be used separately as being favored over acetaminophen (paracetamol) due to the anti-inflammatory properties or in conjunction with acetaminophen (paracetamol) with synergistic effects.<xref ref-type="bibr" rid="article-89519.r25">[25]</xref>
<list list-type="bullet"><list-item><p>&#x000a0;Ibuprofen 
<list list-type="bullet"><list-item><p>Nonselective cyclooxygenase (COX) inhibitor</p></list-item><list-item><p>Kinetics/dynamics
<list list-type="bullet"><list-item><p>Pregnancy category: D (B if not used for prolonged periods, or not near term)</p></list-item><list-item><p>Half-life: 2&#x000a0;to 4 hours</p></list-item><list-item><p>Onset: 30 minutes</p></list-item><list-item><p>Duration: 4&#x000a0;to 6 hours</p></list-item></list>
</p></list-item><list-item><p>Dosing
<list list-type="bullet"><list-item><p>Adult
<list list-type="bullet"><list-item><p>PO: 200&#x000a0;to 400 mg every 4&#x000a0;to 6 hours</p></list-item></list>
</p></list-item><list-item><p>Pediatric
<list list-type="bullet"><list-item><p>PO: 5&#x000a0;to 10 mg/kg every 4&#x000a0;to 6 hours</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Precautions
<list list-type="bullet"><list-item><p>Use the lowest effective dose for the shortest possible duration to reduce the risk of adverse events.</p></list-item><list-item><p>Risk of serious cardiovascular thrombotic events (MI, stroke)</p></list-item><list-item><p>Avoid in patients with recent MI unless the benefit outweighs the risk; monitor for S/S of ischemia</p></list-item><list-item><p>Risk of serious GI events including inflammation, perforation, bleeding, and ulceration</p></list-item></list>
</p></list-item><list-item><p>Contraindications
<list list-type="bullet"><list-item><p>Patients on blood thinners</p></list-item><list-item><p>Infants &#x0003c; 6 months of age; not approved by FDA</p></list-item><list-item><p>Active gastrointestinal bleeding or peptic ulceration</p></list-item><list-item><p>known hypersensitivity reaction to ibuprofen, aspirin, or other NSAIDs</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Ketorolac tromethamine
<list list-type="bullet"><list-item><p>Kinetics/dynamics
<list list-type="bullet"><list-item><p>Pregnancy category: C</p></list-item><list-item><p>Half-life: 2.5 hours</p></list-item><list-item><p>Onset: 1&#x000a0;to 3 minutes</p></list-item><list-item><p>Duration: 5&#x000a0;to 6 hours</p></list-item></list>
</p></list-item><list-item><p>Dosing
<list list-type="bullet"><list-item><p>Adult
<list list-type="bullet"><list-item><p>IV: 15&#x000a0;to 30 mg</p></list-item><list-item><p>IM: 30&#x000a0;to 60 mg</p></list-item></list>
</p></list-item><list-item><p>Pediatric
<list list-type="bullet"><list-item><p>Safety and efficacy not established</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Precautions
<list list-type="bullet"><list-item><p>Do not exceed 5-day duration for any combination of routes/forms</p></list-item><list-item><p>Can cause serious GI events (bleeding, perforation, ulceration); use lowest effective dose and duration to reduce risk</p></list-item><list-item><p>Long-term Tx: risk of renal papillary necrosis, interstitial nephritis, and nephrotic syndrome</p></list-item><list-item><p>Risk of renal decompensation; correct volume depletion before initiation and maintain hydration</p></list-item><list-item><p>Monitor renal function with renal impairment and those at risk</p></list-item><list-item><p>May cause or exacerbate hypertension; monitor during Tx</p></list-item><list-item><p>May cause fluid retention/edema, NaCl retention, hyperkalemia, oliguria, edema, serum urea nitrogen, and creatinine elevations</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Nitroglycerin is an organic nitrite that has potent vasodilatory effects. The first described use for nitroglycerin in medicine dates back to 1867, when Lauder Brunton treated patients with angina. Today nitroglycerin is on the World Health Organization's list of essential medications.&#x000a0;<xref ref-type="bibr" rid="article-89519.r26">[26]</xref> Nitroglycerin causes smooth muscle dilation by decreasing the cytosolic calcium levels. This process occurs through the release of nitrous oxide that stimulates the conversion of guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP), which acts as a cellular messenger. cGMP stimulates protein kinase P, a second messenger that causes a drop in the cytosolic calcium and smooth muscle dilation.
<list list-type="bullet"><list-item><p>Kinetics/dynamics
<list list-type="bullet"><list-item><p>Pregnancy category: C</p></list-item><list-item><p>Half-Life: 1&#x000a0;to 4 minutes</p></list-item><list-item><p>Onset:
<list list-type="bullet"><list-item><p>Antianginal effects: within 2 minutes</p></list-item><list-item><p>Hemodynamic effects: 2 minutes</p></list-item></list>
</p></list-item><list-item><p>Duration:
<list list-type="bullet"><list-item><p>Antianginal effects: up to 30 minutes</p></list-item><list-item><p>Hemodynamic effects: up to 30 minutes</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Dosing
<list list-type="bullet"><list-item><p>Angina pectoris
<list list-type="bullet"><list-item><p>Sublingual - 0.3 mg q 5 minutes</p></list-item><list-item><p>Transdermal - 0.5&#x000a0;to 2 inches every 8 hours</p></list-item></list>
</p></list-item><list-item><p>Congestive heart failure
<list list-type="bullet"><list-item><p>Transdermal - 1.5 inches, increase by 0.5&#x000a0;to 1 inch up to 4 inches</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Precautions
<list list-type="bullet"><list-item><p>Can cause an increase in intracranial pressure and hypotension</p></list-item><list-item><p>Discontinue if blurred vision develops</p></list-item><list-item><p>Headache; dose-related</p></list-item><list-item><p>Do not apply with fingers; do not rub or massage</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>"Among the remedies which it has pleased Almighty God to give to man to relieve his sufferings, none is so universal and so efficacious as opium" Sir Thomas Sydenham, 1680.<xref ref-type="bibr" rid="article-89519.r27">[27]</xref> Opiate pain medications bind directly to (3) different receptors in the brain to include: mu, delta, and kappa. The mu receptor is the primary receptor for opiates and was first described in the 1800s after the formulation discovery for morphine, named after the Greek god of sleep Morpheus. Opiates work by activating a g-protein secondary message system through the coupling of the opiate with the mu-opioid receptor (MOR) in the central nervous system.<xref ref-type="bibr" rid="article-89519.r28">[28]</xref>&#x000a0;Mu receptors are located throughout the body, specifically in the periaqueductal gray (PAG) found in the midbrain. One of the functions of the PAG is to control descending pain modulation through the suppression of pain via enkephalin-producing cells. Gamma-aminobutyric acid (GABA), the chief inhibitory neurotransmitter, plays an important role in suppressing pain by preventing the transmission of pain signals along the nerve.<xref ref-type="bibr" rid="article-89519.r29">[29]</xref> Opiate medications will decrease glutamatergic (excitatory) and GABAergic (inhibitory) activity depending upon the location within the brain and spinal cord. The reduction of glutamatergic synaptic transmission will give the desired properties of analgesia. The reduction in GABAergic activity specifically within the nucleus accumbens allows for an increase in dopamine and gives the "reward" or euphoric effects associated with opiates.</p>
        <list list-type="bullet">
          <list-item>
            <p>Morphine is a derivative of opium extracted from the poppy seeds of the opium poppy. Morphine is an agonist with the mu-opioid receptor (MOR), K-opioid receptor (KOR), and delta-opioid receptor (DOR).&#x000a0; Analgesia, sedation, respiratory depression are associated with the (MOR) activation, whereas miosis (pinpoint pupils), spinal analgesia, and psychotomimetic effects are associated with the (KOR) activation.<xref ref-type="bibr" rid="article-89519.r30">[30]</xref><xref ref-type="bibr" rid="article-89519.r31">[31]</xref>
<list list-type="bullet"><list-item><p>Kinetics/dynamics
<list list-type="bullet"><list-item><p>Pregnancy category: C</p></list-item><list-item><p>Half-life: 1.5&#x000a0;to 4.5 hours (immediate-release forms)</p></list-item><list-item><p>Onset: IV &#x0003c; 5 minutes</p></list-item><list-item><p>Duration: up to 7 hours</p></list-item></list>
</p></list-item><list-item><p>Dosing
<list list-type="bullet"><list-item><p>Adult
<list list-type="bullet"><list-item><p>IV: 2&#x000a0;to 10 mg over 3&#x000a0;to 5 minutes</p></list-item><list-item><p>IM: 5&#x000a0;to 20 mg</p></list-item></list>
</p></list-item><list-item><p>Pediatric:
<list list-type="bullet"><list-item><p>IV / IM: 0.1 to 0.2 mg/kg</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Adverse effects of morphine include CNS and respiratory depression, bradycardia, QT-interval prolongation, miosis, constipation (ileus), urinary retention, allergic reaction related to histamine release from mast cells, hypogonadism, dependency, and addiction.<xref ref-type="bibr" rid="article-89519.r31">[31]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Fentanyl is a mu-selective synthetic opiate first synthesized in the 1960s and medically approved for pain control and medication-assisted intubation. Its potency is approximately 100 times more than morphine.<xref ref-type="bibr" rid="article-89519.r32">[32]</xref>
<list list-type="bullet"><list-item><p>Kinetics/dynamics
<list list-type="bullet"><list-item><p>Pregnancy category: B</p></list-item><list-item><p>Half-life: 7.1 hours</p></list-item><list-item><p>Onset: Immediately</p></list-item><list-item><p>Duration: up to 72 hours</p></list-item></list>
</p></list-item><list-item><p>Dosing
<list list-type="bullet"><list-item><p>Adult
<list list-type="bullet"><list-item><p>IV / IM: 1&#x000a0;to 2 mcg/kg (usual dose 50&#x000a0;to 100 mcg)</p></list-item></list>
</p></list-item><list-item><p>Pediatric
<list list-type="bullet"><list-item><p>IV / IM: 1 mcg/kg</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Adverse effects include respiratory depression, somnolence, asthenia (weakness), constipation, urinary retention. Rapid administration can produce chest wall rigidity.<xref ref-type="bibr" rid="article-89519.r32">[32]</xref></p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Hydromorphone (dihydromorphinone) is a synthetic opiate patented in 1923. It exerts its effects on mu-opioid receptors. It has a high potency (0.9&#x000a0;to 1.2 mg) equianalgesic compared to morphine sulfate (10 mg) and is used to treat moderate to severe pain.<xref ref-type="bibr" rid="article-89519.r33">[33]</xref><xref ref-type="bibr" rid="article-89519.r34">[34]</xref>
<list list-type="bullet"><list-item><p>Kinetics/dynamics
<list list-type="bullet"><list-item><p>Pregnancy category: C (D if used near term, according to some authorities)</p></list-item><list-item><p>Half-life: 2&#x000a0;to 4 hours</p></list-item><list-item><p>Onset: 10&#x000a0;to 15 minutes</p></list-item><list-item><p>Duration: 2&#x000a0;to 3 hours (IV)</p></list-item></list>
</p></list-item><list-item><p>Dosing
<list list-type="bullet"><list-item><p>Adult
<list list-type="bullet"><list-item><p>IV: 0.2&#x000a0;to 1 mg every 2&#x000a0;to 3 hours</p></list-item><list-item><p>IM: 1&#x000a0;to 2 mg every 2&#x000a0;to 3 hours</p></list-item></list>
</p></list-item><list-item><p>Pediatric
<list list-type="bullet"><list-item><p>IV/IM: 0.015 mg/kg slow IV/IM every 4 - 6 hours</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Adverse effects include risk of respiratory depression, bronchospasm, urinary retention, dizziness, circulatory depression, nausea, itchiness, and constipation</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>Benzodiazepine (BZD)&#x000a0;is a classification of medications that act as positive allosteric modulators at the BZD receptor (gamma-aminobutyric acid (GABA)-A receptor) site, which&#x000a0;is a&#x000a0;ligand-gated chloride-selective ion channel. GABA is the primary inhibitory neurotransmitter in the central nervous system. BZDs classification is in terms of the half-life elimination with a short-acting&#x000a0;half-life of&#x000a0;1&#x000a0;to 12 hours, the intermediate-acting half-life of 12&#x000a0;to 40 hours, and long-acting of 40&#x000a0;to 250 hours.&#x000a0;Common side effects for all BZDs include lethargy, fatigue, and drowsiness. Impaired motor coordination, blurring of vision, slurring of speech, mood swings with feelings of euphoria can present in patients with higher dosage consumption.<xref ref-type="bibr" rid="article-89519.r35">[35]</xref>&#x000a0;The different formulations of benzodiazepines have different routes of degradation, with the majority of them being first metabolized by hepatic oxidation and then undergo glucuronidation, these being chlordiazepoxide, diazepam, and midazolam. There are (3) that only undergo hepatic glucuronidation, which is&#x000a0;lorazepam, oxazepam, and temazepam. Administration of benzodiazepine type medication to elderly patients and those with liver disease requires careful consideration because the benzodiazepine oxidation decreases.<xref ref-type="bibr" rid="article-89519.r36">[36]</xref>&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Diazepam
<list list-type="bullet"><list-item><p>Kinetics/dynamics
<list list-type="bullet"><list-item><p>Pregnancy category: D</p></list-item><list-item><p>Half-life: 20 to 70 hours (active metabolite)</p></list-item><list-item><p>Onset: 1 to 5 minutes (IV / IM)</p></list-item><list-item><p>Duration: 15 to 60 minutes</p></list-item></list>
</p></list-item><list-item><p>Dosing
<list list-type="bullet"><list-item><p>Adult
<list list-type="bullet"><list-item><p>Alcohol withdrawal
<list list-type="bullet"><list-item><p>IV: 10 mg initially followed by 5&#x000a0;to 10 mg every 1&#x000a0;to 4 hours</p></list-item></list>
</p></list-item><list-item><p>Muscle relaxant
<list list-type="bullet"><list-item><p>IV/IM: 5&#x000a0;to 10 mg every 3&#x000a0;to 4 hours</p></list-item></list>
</p></list-item><list-item><p>Seizure disorder / status epilepticus
<list list-type="bullet"><list-item><p>IV/IM: 5&#x000a0;to 10 mg/dose every 10&#x000a0;to 15 minutes</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Pediatric
<list list-type="bullet"><list-item><p>Muscle relaxant
<list list-type="bullet"><list-item><p>IV/IM: 0.04&#x000a0;to 0.2 mg/kg every 2&#x000a0;to 4 hours</p></list-item></list>
</p></list-item><list-item><p>Seizure disorder / status epilepticus
<list list-type="bullet"><list-item><p>Neonate (&#x0003c; 28 days)
<list list-type="bullet"><list-item><p>IV: 0.3&#x000a0;to 0.75 mg/kg every 15&#x000a0;to 30 minutes x 2&#x000a0;to 3 doses</p></list-item></list>
</p></list-item><list-item><p>&#x0003e; 1 month
<list list-type="bullet"><list-item><p>IV: 0.2&#x000a0;to 0.5 mg/kg every 15&#x000a0;to 30 minutes x 2 to 3 doses</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Precautions
<list list-type="bullet"><list-item><p>Not recommended for medication-assisted intubation (MAI) / rapid sequence intubation (RSI) because of the time of onset but frequently used for long-term sedation following intubation.&#x000a0;</p></list-item><list-item><p>It requires propylene glycol as a diluent, and there are reports of propylene glycol toxicity associated with long-term infusions.</p></list-item><list-item><p>Undergoes hepatic oxidation and glucuronidation if metabolized</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Lorazepam&#x000a0;<xref ref-type="bibr" rid="article-89519.r37">[37]</xref>
<list list-type="bullet"><list-item><p>Kinetics/dynamics
<list list-type="bullet"><list-item><p>Pregnancy category: D</p></list-item><list-item><p>Half-life: 8&#x000a0;to 20 hours</p></list-item><list-item><p>Onset:
<list list-type="bullet"><list-item><p>IV: 1&#x000a0;to 5 minutes</p></list-item><list-item><p>IM: 15&#x000a0;to 30 minutes</p></list-item></list>
</p></list-item><list-item><p>Duration: 12&#x000a0;to 24 hours</p></list-item></list>
</p></list-item><list-item><p>Dosing
<list list-type="bullet"><list-item><p>Adult
<list list-type="bullet"><list-item><p>Sedation
<list list-type="bullet"><list-item><p>&#x000a0;IV: 0.02&#x000a0;to 0.06 mg/kg</p></list-item></list>
</p></list-item><list-item><p>Seizure disorder / status epilepticus
<list list-type="bullet"><list-item><p>IV: 2&#x000a0;to 4 mg</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Pediatric
<list list-type="bullet"><list-item><p>Sedation
<list list-type="bullet"><list-item><p>IV: 0.025&#x000a0;to 0.05 mg/kg</p></list-item></list>
</p></list-item><list-item><p>Seizure disorder / status epilepticus
<list list-type="bullet"><list-item><p>IV: 0.05&#x000a0;to 0.1 mg/kg every 10&#x000a0;to 15 minutes</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Safer to use in patients with impaired liver function than other benzodiazepines because it only requires hepatic glucuronidation into lorazepam-glucuronide.<xref ref-type="bibr" rid="article-89519.r36">[36]</xref></p></list-item><list-item><p>Precautions
<list list-type="bullet"><list-item><p>Not recommended for MAI / RSI because of the time of onset but frequently used for long-term sedation following intubation.&#x000a0;</p></list-item><list-item><p>It requires propylene glycol as a diluent, and there are reports of propylene glycol toxicity associated with long-term infusions.</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
          <list-item>
            <p>Midazolam <xref ref-type="bibr" rid="article-89519.r38">[38]</xref><xref ref-type="bibr" rid="article-89519.r39">[39]</xref><xref ref-type="bibr" rid="article-89519.r40">[40]</xref><xref ref-type="bibr" rid="article-89519.r39">[39]</xref><xref ref-type="bibr" rid="article-89519.r38">[38]</xref>
<list list-type="bullet"><list-item><p>Kinetics/dynamics
<list list-type="bullet"><list-item><p>Pregnancy category: D</p></list-item><list-item><p>Half-life: 1.2&#x000a0;to 12.3 hours</p></list-item><list-item><p>Onset:
<list list-type="bullet"><list-item><p>IV: 2&#x000a0;to 3 minutes</p></list-item><list-item><p>IM 15 minutes</p></list-item></list>
</p></list-item><list-item><p>Duration: 1&#x000a0;to 4 hours</p></list-item></list>
</p></list-item><list-item><p>Dosing
<list list-type="bullet"><list-item><p>Adult
<list list-type="bullet"><list-item><p>MAI / RSI
<list list-type="bullet"><list-item><p>IV: 0.1 to 0.3 mg/kg IV push, with a time to initial effect of roughly 30 to 60 seconds, and a duration of action of 15 to 30 minutes</p></list-item></list>
Sedation
<list list-type="bullet"><list-item><p>IV: 0.5&#x000a0;to 1 mg</p></list-item></list>
</p></list-item><list-item><p>Seizure disorder / status epilepticus
<list list-type="bullet"><list-item><p>IV/IM/IN: 2&#x000a0;to 4 mg every 10&#x000a0;to 15 minutes</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>&#x000a0;Pediatric
<list list-type="bullet"><list-item><p>MAI / RSI
<list list-type="bullet"><list-item><p>IV: 0.1 to 0.3 mg/kg IV push, with a time to initial effect of roughly 30 to 60 seconds, and a duration of action of 15 to 30 minutes</p></list-item></list>
Sedation
<list list-type="bullet"><list-item><p>IV: 0.05 - 0.1 mg/kg</p></list-item></list>
</p></list-item><list-item><p>Seizure disorder / status epilepticus <xref ref-type="bibr" rid="article-89519.r41">[41]</xref>
<list list-type="bullet"><list-item><p>IV: 2&#x000a0;to 4 mg every 10&#x000a0;to 15 minutes</p></list-item><list-item><p>IM: 0.1&#x000a0;to 0.5 mg/kg</p></list-item><list-item><p>IN: 0.1&#x000a0;to 0.2 mg/kg</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Precautions
<list list-type="bullet"><list-item><p>Not recommended for MAI / RSI because of the time of onset but frequently used for long-term sedation following intubation.&#x000a0;</p></list-item><list-item><p>Undergoes hepatic oxidation and glucuronidation for metabolism</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>NMDA (N-methyl-D-aspartate) receptor antagonists are a group of medications that can induce a state of dissociation and, therefore, can produce anesthesia characterized by loss of short-term memory (amnesia), inability to feel pain (analgesia), and decreased sensitivity to pain (catalepsy). The primary role is to inhibit the action of glutamate, which is the primary excitatory neurotransmitter of the brain and spinal cord. These medications have been used to treat acute and chronic pain syndromes.&#x000a0;</p>
        <list list-type="bullet">
          <list-item>
            <p>Ketamine&#x000a0;
<list list-type="bullet"><list-item><p>First described in 1966 by Corssen and Domino as a human anesthetic.<xref ref-type="bibr" rid="article-89519.r42">[42]</xref> Ketamine has (3) primary functions being: hypnotic (sleep-producing), analgesic (pain-relieving), and amnestic (short-term memory loss) effects, which are mediated by N-methyl-d-aspartate (NMDA), opioid, muscarinic, and different voltage-gated receptors. Additionally, ketamine causes bronchodilation and stimulation of the sympathetic nervous system and cardiovascular system, which can cause tachycardia and hypertension.<xref ref-type="bibr" rid="article-89519.r43">[43]</xref><xref ref-type="bibr" rid="article-89519.r44">[44]</xref><xref ref-type="bibr" rid="article-89519.r45">[45]</xref> Ketamine has become widely used as an induction agent during medication-assisted intubation for patients with asthma and COPD because of the bronchodilation properties.</p></list-item><list-item><p>Kinectics/dynamics
<list list-type="bullet"><list-item><p>Pregnancy category: C</p></list-item><list-item><p>Half-life:</p></list-item><list-item><p>Onset:
<list list-type="bullet"><list-item><p>IV: 30 seconds</p></list-item><list-item><p>IM: 3&#x000a0;to 4 minutes</p></list-item></list>
</p></list-item><list-item><p>Duration:
<list list-type="bullet"><list-item><p>IV: 5 to10 minutes</p></list-item><list-item><p>IM: 12&#x000a0;to 25 minutes</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Dosing
<list list-type="bullet"><list-item><p>Adult
<list list-type="bullet"><list-item><p>MAI / RSI
<list list-type="bullet"><list-item><p>IV: 1&#x000a0;to 2 mg/kg</p></list-item><list-item><p>IM: 4 mg/kg</p></list-item></list>
</p></list-item><list-item><p>Sedation
<list list-type="bullet"><list-item><p>IV: 1&#x000a0;to 2 mg/kg</p></list-item><list-item><p>IM: 4 mg/kg</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Pediatric
<list list-type="bullet"><list-item><p>MAI / RSI
<list list-type="bullet"><list-item><p>IV: 1&#x000a0;to 2 mg/kg</p></list-item><list-item><p>IM: 4 mg/kg</p></list-item></list>
</p></list-item><list-item><p>Sedation
<list list-type="bullet"><list-item><p>IV: 1&#x000a0;to 2 mg/kg</p></list-item><list-item><p>IM: 4 mg/kg</p></list-item></list>
</p></list-item></list>
</p></list-item></list>
</p></list-item><list-item><p>Precautions
<list list-type="bullet"><list-item><p>&#x0003e; 10 % - hypertension and tachycardia</p></list-item><list-item><p>&#x0003c; 1 % - hypersalivation, increased IOP, increased metabolic rate, hypertonia, laryngospasm</p></list-item></list>
</p></list-item></list>
</p>
          </list-item>
        </list>
        <p>(kinectics / dynamics / dosages / precautions obtained from PEPID online)</p>
      </sec>
      <sec id="article-89519.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Of the five known most frequent causes for individuals to call for emergency services, three of them are pain-related ("wounds, fractures, minor injuries," "accidents," "chest pain/heart disease").<xref ref-type="bibr" rid="article-89519.r3">[3]</xref> This means that prehospital providers have a potential impact on the pain/suffering of individuals that rely on the services provided. Prehospital providers need to assess patients for pain with appropriate validated tools.&#x000a0; Prehospital providers have pharmacologic and non-pharmacologic modalities at their disposal to render compassionate care to the individuals they are treating. It is crucial to be familiar with the different agents available to include indications, contraindications, adverse risk factors, dosages, and potential reversal agents. Likewise, prehospital providers should be more willing to utilize non-pharmacologic modalities for pain management. An interprofessional team of providers, including EMS personnel, physicians, pharmacists, and nurses, can improve pain evaluation and treatment in the prehospital setting. [Level 5]</p>
      </sec>
      <sec id="article-89519.s4">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=89519&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=89519">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/89519/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=89519">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-89519.s5">
        <title>References</title>
        <ref id="article-89519.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McGuire</surname>
                <given-names>DB</given-names>
              </name>
              <name>
                <surname>Kaiser</surname>
                <given-names>KS</given-names>
              </name>
              <name>
                <surname>Haisfield-Wolfe</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Iyamu</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Pain Assessment in Noncommunicative Adult Palliative Care Patients.</article-title>
            <source>Nurs Clin North Am</source>
            <year>2016</year>
            <month>Sep</month>
            <volume>51</volume>
            <issue>3</issue>
            <fpage>397</fpage>
            <page-range>397-431</page-range>
            <pub-id pub-id-type="pmid">27497016</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anand</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Hickey</surname>
                <given-names>PR</given-names>
              </name>
            </person-group>
            <article-title>Pain and its effects in the human neonate and fetus.</article-title>
            <source>N Engl J Med</source>
            <year>1987</year>
            <month>Nov</month>
            <day>19</day>
            <volume>317</volume>
            <issue>21</issue>
            <fpage>1321</fpage>
            <page-range>1321-9</page-range>
            <pub-id pub-id-type="pmid">3317037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>M&#x000f8;ller</surname>
                <given-names>TP</given-names>
              </name>
              <name>
                <surname>Ersb&#x000f8;ll</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Tolstrup</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>&#x000d8;stergaard</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Viereck</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Overton</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Folke</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Lippert</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Why and when citizens call for emergency help: an observational study of 211,193 medical emergency calls.</article-title>
            <source>Scand J Trauma Resusc Emerg Med</source>
            <year>2015</year>
            <month>Nov</month>
            <day>04</day>
            <volume>23</volume>
            <fpage>88</fpage>
            <pub-id pub-id-type="pmid">26530307</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Parker</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rodgers</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Management of pain in pre-hospital settings.</article-title>
            <source>Emerg Nurse</source>
            <year>2015</year>
            <month>Jun</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>16</fpage>
            <page-range>16-21; quiz 23</page-range>
            <pub-id pub-id-type="pmid">26050779</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friesgaard</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Riddervold</surname>
                <given-names>IS</given-names>
              </name>
              <name>
                <surname>Kirkegaard</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Christensen</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Nikolajsen</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Acute pain in the prehospital setting: a register-based study of 41.241 patients.</article-title>
            <source>Scand J Trauma Resusc Emerg Med</source>
            <year>2018</year>
            <month>Jul</month>
            <day>03</day>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>53</fpage>
            <pub-id pub-id-type="pmid">29970130</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Galinski</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ruscev</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gonzalez</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kavas</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ameur</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Biens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Lapostolle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Adnet</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Prevalence and management of acute pain in prehospital emergency medicine.</article-title>
            <source>Prehosp Emerg Care</source>
            <year>2010</year>
            <season>Jul-Sep</season>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>334</fpage>
            <page-range>334-9</page-range>
            <pub-id pub-id-type="pmid">20507221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alonso-Serra</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Wesley</surname>
                <given-names>K</given-names>
              </name>
              <collab>National Association of EMS Physicians Standards and Clinical Practices Committee</collab>
            </person-group>
            <article-title>Prehospital pain management.</article-title>
            <source>Prehosp Emerg Care</source>
            <year>2003</year>
            <season>Oct-Dec</season>
            <volume>7</volume>
            <issue>4</issue>
            <fpage>482</fpage>
            <page-range>482-8</page-range>
            <pub-id pub-id-type="pmid">14582104</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cousins</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Lynch</surname>
                <given-names>ME</given-names>
              </name>
            </person-group>
            <article-title>The Declaration Montreal: access to pain management is a fundamental human right.</article-title>
            <source>Pain</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>152</volume>
            <issue>12</issue>
            <fpage>2673</fpage>
            <page-range>2673-2674</page-range>
            <pub-id pub-id-type="pmid">21995880</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McManus</surname>
                <given-names>JG</given-names>
              </name>
              <name>
                <surname>Sallee</surname>
                <given-names>DR</given-names>
              </name>
            </person-group>
            <article-title>Pain management in the prehospital environment.</article-title>
            <source>Emerg Med Clin North Am</source>
            <year>2005</year>
            <month>May</month>
            <volume>23</volume>
            <issue>2</issue>
            <fpage>415</fpage>
            <page-range>415-31</page-range>
            <pub-id pub-id-type="pmid">15829390</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Page</surname>
                <given-names>GG</given-names>
              </name>
            </person-group>
            <article-title>Are there long-term consequences of pain in newborn or very young infants?</article-title>
            <source>J Perinat Educ</source>
            <year>2004</year>
            <season>Summer</season>
            <volume>13</volume>
            <issue>3</issue>
            <fpage>10</fpage>
            <page-range>10-7</page-range>
            <pub-id pub-id-type="pmid">17273395</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Srouji</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ratnapalan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Schneeweiss</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Pain in children: assessment and nonpharmacological management.</article-title>
            <source>Int J Pediatr</source>
            <year>2010</year>
            <volume>2010</volume>
            <pub-id pub-id-type="pmid">20706640</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lord</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Cui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>AM</given-names>
              </name>
            </person-group>
            <article-title>The impact of patient sex on paramedic pain management in the prehospital setting.</article-title>
            <source>Am J Emerg Med</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>5</issue>
            <fpage>525</fpage>
            <page-range>525-9</page-range>
            <pub-id pub-id-type="pmid">19497456</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hennes</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Pirrallo</surname>
                <given-names>RG</given-names>
              </name>
            </person-group>
            <article-title>Prehospital pain management: a comparison of providers' perceptions and practices.</article-title>
            <source>Prehosp Emerg Care</source>
            <year>2005</year>
            <season>Jan-Mar</season>
            <volume>9</volume>
            <issue>1</issue>
            <fpage>32</fpage>
            <page-range>32-9</page-range>
            <pub-id pub-id-type="pmid">16036825</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>French</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Ramaker</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Education on prehospital pain management: a follow-up study.</article-title>
            <source>West J Emerg Med</source>
            <year>2013</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>96</fpage>
            <page-range>96-102</page-range>
            <pub-id pub-id-type="pmid">23599840</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marqui&#x000e9;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Raufaste</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Lauque</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Marin&#x000e9;</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Ecoiffier</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Sorum</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Pain rating by patients and physicians: evidence of systematic pain miscalibration.</article-title>
            <source>Pain</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>102</volume>
            <issue>3</issue>
            <fpage>289</fpage>
            <page-range>289-296</page-range>
            <pub-id pub-id-type="pmid">12670671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Witt</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Coynor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Edwards</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bradshaw</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>A Guide to Pain Assessment and Management in the Neonate.</article-title>
            <source>Curr Emerg Hosp Med Rep</source>
            <year>2016</year>
            <volume>4</volume>
            <fpage>1</fpage>
            <page-range>1-10</page-range>
            <pub-id pub-id-type="pmid">27073748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Merkel</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Voepel-Lewis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Shayevitz</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Malviya</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>The FLACC: a behavioral scale for scoring postoperative pain in young children.</article-title>
            <source>Pediatr Nurs</source>
            <year>1997</year>
            <season>May-Jun</season>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>293</fpage>
            <page-range>293-7</page-range>
            <pub-id pub-id-type="pmid">9220806</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Voepel-Lewis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zanotti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Dammeyer</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Merkel</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Reliability and validity of the face, legs, activity, cry, consolability behavioral tool in assessing acute pain in critically ill patients.</article-title>
            <source>Am J Crit Care</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>19</volume>
            <issue>1</issue>
            <fpage>55</fpage>
            <page-range>55-61; quiz 62</page-range>
            <pub-id pub-id-type="pmid">20045849</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wong</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>CM</given-names>
              </name>
            </person-group>
            <article-title>Pain in children: comparison of assessment scales.</article-title>
            <source>Pediatr Nurs</source>
            <year>1988</year>
            <season>Jan-Feb</season>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>9</fpage>
            <page-range>9-17</page-range>
            <pub-id pub-id-type="pmid">3344163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Haefeli</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Elfering</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Pain assessment.</article-title>
            <source>Eur Spine J</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>15 Suppl 1</volume>
            <issue>Suppl 1</issue>
            <fpage>S17</fpage>
            <page-range>S17-24</page-range>
            <pub-id pub-id-type="pmid">16320034</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pak</surname>
                <given-names>SC</given-names>
              </name>
              <name>
                <surname>Micalos</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Maria</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Lord</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Nonpharmacological interventions for pain management in paramedicine and the emergency setting: a review of the literature.</article-title>
            <source>Evid Based Complement Alternat Med</source>
            <year>2015</year>
            <volume>2015</volume>
            <fpage>873039</fpage>
            <pub-id pub-id-type="pmid">25918548</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Taddio</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Hancock</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>RW</given-names>
              </name>
              <name>
                <surname>Stephens</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Atenafu</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Beyene</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Koren</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Katz</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness of sucrose analgesia in newborns undergoing painful medical procedures.</article-title>
            <source>CMAJ</source>
            <year>2008</year>
            <month>Jul</month>
            <day>01</day>
            <volume>179</volume>
            <issue>1</issue>
            <fpage>37</fpage>
            <page-range>37-43</page-range>
            <pub-id pub-id-type="pmid">18591525</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleischman</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Frazer</surname>
                <given-names>DG</given-names>
              </name>
              <name>
                <surname>Daya</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Jui</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Newgard</surname>
                <given-names>CD</given-names>
              </name>
            </person-group>
            <article-title>Effectiveness and safety of fentanyl compared with morphine for out-of-hospital analgesia.</article-title>
            <source>Prehosp Emerg Care</source>
            <year>2010</year>
            <season>Apr-Jun</season>
            <volume>14</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-75</page-range>
            <pub-id pub-id-type="pmid">20199230</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r24">
          <label>24</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Saad</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Mathew</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Nonsteroidal Anti-Inflammatory Drugs Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>7</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">30252262</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r25">
          <label>25</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ershad</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Ameer</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Vearrier</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <chapter-title>Ibuprofen Toxicity</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>8</day>
            <pub-id pub-id-type="pmid">30252334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marsh</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marsh</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>A short history of nitroglycerine and nitric oxide in pharmacology and physiology.</article-title>
            <source>Clin Exp Pharmacol Physiol</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>27</volume>
            <issue>4</issue>
            <fpage>313</fpage>
            <page-range>313-9</page-range>
            <pub-id pub-id-type="pmid">10779131</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Batmanabane</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Why patients in pain cannot get "God's own medicine?".</article-title>
            <source>J Pharmacol Pharmacother</source>
            <year>2014</year>
            <month>Apr</month>
            <volume>5</volume>
            <issue>2</issue>
            <fpage>81</fpage>
            <page-range>81-2</page-range>
            <pub-id pub-id-type="pmid">24799809</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Traynor</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>&#x003bc;-Opioid receptors and regulators of G protein signaling (RGS) proteins: from a symposium on new concepts in mu-opioid pharmacology.</article-title>
            <source>Drug Alcohol Depend</source>
            <year>2012</year>
            <month>Mar</month>
            <day>01</day>
            <volume>121</volume>
            <issue>3</issue>
            <fpage>173</fpage>
            <page-range>173-80</page-range>
            <pub-id pub-id-type="pmid">22129844</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jasmin</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>MV</given-names>
              </name>
              <name>
                <surname>Ohara</surname>
                <given-names>PT</given-names>
              </name>
            </person-group>
            <article-title>GABA puts a stop to pain.</article-title>
            <source>Curr Drug Targets CNS Neurol Disord</source>
            <year>2004</year>
            <month>Dec</month>
            <volume>3</volume>
            <issue>6</issue>
            <fpage>487</fpage>
            <page-range>487-505</page-range>
            <pub-id pub-id-type="pmid">15578966</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kelly</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and ligand bias at the &#x003bc;-opioid receptor.</article-title>
            <source>Br J Pharmacol</source>
            <year>2013</year>
            <month>Aug</month>
            <volume>169</volume>
            <issue>7</issue>
            <fpage>1430</fpage>
            <page-range>1430-46</page-range>
            <pub-id pub-id-type="pmid">23646826</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r31">
          <label>31</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Murphy</surname>
                <given-names>PB</given-names>
              </name>
              <name>
                <surname>Bechmann</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barrett</surname>
                <given-names>MJ</given-names>
              </name>
            </person-group>
            <chapter-title>Morphine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>22</day>
            <pub-id pub-id-type="pmid">30252371</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r32">
          <label>32</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ramos-Matos</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Bistas</surname>
                <given-names>KG</given-names>
              </name>
              <name>
                <surname>Lopez-Ojeda</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <chapter-title>Fentanyl</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>29</day>
            <pub-id pub-id-type="pmid">29083586</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r33">
          <label>33</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Abi-Aad</surname>
                <given-names>KR</given-names>
              </name>
              <name>
                <surname>Derian</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <chapter-title>Hydromorphone</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>8</month>
            <day>17</day>
            <pub-id pub-id-type="pmid">29261877</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mahler</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Forrest</surname>
                <given-names>WH</given-names>
              </name>
            </person-group>
            <article-title>Relative analgesic potencies of morphine and hydromorphone in postoperative pain.</article-title>
            <source>Anesthesiology</source>
            <year>1975</year>
            <month>May</month>
            <volume>42</volume>
            <issue>5</issue>
            <fpage>602</fpage>
            <page-range>602-7</page-range>
            <pub-id pub-id-type="pmid">48347</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Griffin</surname>
                <given-names>CE</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Bueno</surname>
                <given-names>FR</given-names>
              </name>
              <name>
                <surname>Kaye</surname>
                <given-names>AD</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepine pharmacology and central nervous system-mediated effects.</article-title>
            <source>Ochsner J</source>
            <year>2013</year>
            <season>Summer</season>
            <volume>13</volume>
            <issue>2</issue>
            <fpage>214</fpage>
            <page-range>214-23</page-range>
            <pub-id pub-id-type="pmid">23789008</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Peppers</surname>
                <given-names>MP</given-names>
              </name>
            </person-group>
            <article-title>Benzodiazepines for alcohol withdrawal in the elderly and in patients with liver disease.</article-title>
            <source>Pharmacotherapy</source>
            <year>1996</year>
            <season>Jan-Feb</season>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>49</fpage>
            <page-range>49-57</page-range>
            <pub-id pub-id-type="pmid">8700792</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r37">
          <label>37</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Ghiasi</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Bhansali</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Marwaha</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <chapter-title>Lorazepam</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>1</month>
            <day>31</day>
            <pub-id pub-id-type="pmid">30422485</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silbergleit</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Durkalski</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Conwit</surname>
                <given-names>R</given-names>
              </name>
              <collab>NETT Investigators</collab>
            </person-group>
            <article-title>Lessons from the RAMPART study--and which is the best route of administration of benzodiazepines in status epilepticus.</article-title>
            <source>Epilepsia</source>
            <year>2013</year>
            <month>Sep</month>
            <volume>54 Suppl 6</volume>
            <issue>0 6</issue>
            <fpage>74</fpage>
            <page-range>74-7</page-range>
            <pub-id pub-id-type="pmid">24001080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shtull-Leber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Silbergleit</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Meurer</surname>
                <given-names>WJ</given-names>
              </name>
            </person-group>
            <article-title>Pre-hospital midazolam for benzodiazepine-treated seizures before and after the Rapid Anticonvulsant Medication Prior to Arrival Trial: A national observational cohort study.</article-title>
            <source>PLoS One</source>
            <year>2017</year>
            <volume>12</volume>
            <issue>3</issue>
            <fpage>e0173539</fpage>
            <pub-id pub-id-type="pmid">28306741</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silbergleit</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lowenstein</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Durkalski</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Conwit</surname>
                <given-names>R</given-names>
              </name>
              <collab>Neurological Emergency Treatment Trials (NETT) Investigators</collab>
            </person-group>
            <article-title>RAMPART (Rapid Anticonvulsant Medication Prior to Arrival Trial): a double-blind randomized clinical trial of the efficacy of intramuscular midazolam versus intravenous lorazepam in the prehospital treatment of status epilepticus by paramedics.</article-title>
            <source>Epilepsia</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>52 Suppl 8</volume>
            <issue>Suppl 8</issue>
            <fpage>45</fpage>
            <page-range>45-7</page-range>
            <pub-id pub-id-type="pmid">21967361</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r41">
          <label>41</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Silverman</surname>
                <given-names>EC</given-names>
              </name>
              <name>
                <surname>Sporer</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Lemieux</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Koenig</surname>
                <given-names>KL</given-names>
              </name>
              <name>
                <surname>Gausche-Hill</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rudnick</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Salvucci</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Gilbert</surname>
                <given-names>GH</given-names>
              </name>
            </person-group>
            <article-title>Prehospital Care for the Adult and Pediatric Seizure Patient: Current Evidence-based Recommendations.</article-title>
            <source>West J Emerg Med</source>
            <year>2017</year>
            <month>Apr</month>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>419</fpage>
            <page-range>419-436</page-range>
            <pub-id pub-id-type="pmid">28435493</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r42">
          <label>42</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Vlisides</surname>
                <given-names>PE</given-names>
              </name>
            </person-group>
            <article-title>Ketamine: 50 Years of Modulating the Mind.</article-title>
            <source>Front Hum Neurosci</source>
            <year>2016</year>
            <volume>10</volume>
            <fpage>612</fpage>
            <pub-id pub-id-type="pmid">27965560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r43">
          <label>43</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Rosenbaum</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Palacios</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <chapter-title>Ketamine</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>5</month>
            <day>26</day>
            <pub-id pub-id-type="pmid">29262083</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r44">
          <label>44</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sinner</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Graf</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Ketamine.</article-title>
            <source>Handb Exp Pharmacol</source>
            <year>2008</year>
            <issue>182</issue>
            <fpage>313</fpage>
            <page-range>313-33</page-range>
            <pub-id pub-id-type="pmid">18175098</pub-id>
          </element-citation>
        </ref>
        <ref id="article-89519.r45">
          <label>45</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gao</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Rejaei</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Ketamine use in current clinical practice.</article-title>
            <source>Acta Pharmacol Sin</source>
            <year>2016</year>
            <month>Jul</month>
            <volume>37</volume>
            <issue>7</issue>
            <fpage>865</fpage>
            <page-range>865-72</page-range>
            <pub-id pub-id-type="pmid">27018176</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
